EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis

 EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis

EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis

Shots:

  • The CHMP has adopted the positive opinion recommending the approval of Theramex’s  Livogiva (biosimilar, teriparatide) intended for the treatment of osteoporosis and will be available as a solution for injection (20 micrograms/80 microliters)
  • The CHMP has also recommend marketing authorization to EuroGenerics’ Qutavina (biosimilar, teriparatide) to treat osteoporosis, also available as a solution for injection (20 micrograms/80 microliters)
  • Both Livogiva and Qutavina are the biosimilar referencing Lilly’s Forsteo (teriparatide) which has received authorization in EU in 2003

Theramex, EuroGenerics to read full press release/ article | Ref: EMA | Image: Theramex & EuroGenerics

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post